Petosemtamab MCLA 158,95.00%
产品编号：Bellancom-P99406| CAS NO：2213450-26-9
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，
Petosemtamab MCLA 158
| 产品介绍 | Petosemtamab (MCLA 158) 是一种抗EGFR (Kd: 0.22 nM) 和抗 LGR5 (Kd: 0.86 nM) 单克隆抗体 (mAb)。Petosemtamab 导致 LGR5+ 癌细胞中的 EGFR 信号传导阻断和受体降解。Petosemtamab 可用于头颈部鳞状细胞癌 (HNSCC)、转移性结直肠癌 (CRC) 等实体瘤的研究。 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC). | ||||||||
| 体外研究 |
MCLA-158 (1 µg/mL，24 或 72 小时) 导致 EGFR+/LGR5+ 结直肠癌类器官中的 EGFR 降解。 西域 has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis
|
||||||||
| 体内研究 (In Vivo) |
MCLA-158 (25 mg/kg/周，静脉注射，持续 6 周) 导致食管鳞癌、胃腺癌和头颈部 PDX 模型的肿瘤消退。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
| 体内研究 |
MCLA-158 (25 mg/kg/周，静脉注射，持续 6 周) 导致食管鳞癌、胃腺癌和头颈部 PDX 模型的肿瘤消退。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
| 体内研究 |
MCLA-158 (25 mg/kg/周，静脉注射，持续 6 周) 导致食管鳞癌、胃腺癌和头颈部 PDX 模型的肿瘤消退。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
| 性状 | Liquid | ||||||||
| 溶解性数据 | |||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. | ||||||||
| 参考文献 |
浙公网安备 33010802013016号